Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famotidine for Outpatients With COVID-19
NCT04565392Phase 4Withdrawn
- Sponsor
- drpykessupplements.com
- Start
- May 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, triple-blind trial in coronavirus disease 2019 (COVID-19) comparing Famotidine Arm with Placebo Arm (2 arms). Primary endpoints: Clinical Course Binary Outcome at 30 days and Serious Adverse Events at 30 days. Planned start May 2021; status: withdrawn.
02
Drugs
famotidine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04565392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04565392.